Bioequivalence study of famotidine 40 mg tablet
Not Applicable
Recruiting
- Conditions
- In this research, no disease is studied..
- Registration Number
- IRCT20230222057495N12
- Lead Sponsor
- Ramopharmin Pharmaceutical Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Healthy volunteer between 18 and 55 years old.
Body mass index less than 30 kg per square meter.
All candidates must be non-smokers.
Exclusion Criteria
Blood pressure less than 90 on 60 mm Hg or more than 140 on 90 mm Hg.
Consumption of any drug, alcohol or tobacco within 2 weeks before receiving the drug
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Maximum plasma concentration of famotidine. Timepoint: Before taking the medicine and: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300, 360, 420, 600 and 720 minutes after taking the medicine. Method of measurement: Liquid chromatography-mass spectrometry.
- Secondary Outcome Measures
Name Time Method